Williams College · Williamstown, MA
The Williams Business Review

Macroeconomy · Business · Markets

Business

Patent Cliffs, Tariffs, and Rising Rates: What’s Driving Biopharma M&A

Looming patent cliffs are pushing big pharma to buy despite rising interest rates, while new U.S. tariffs reshape what it buys and where it builds.

Mia Kincade· November 16, 2026
Patent Cliffs, Tariffs, and Rising Rates: What’s Driving Biopharma M&A

In early November, AstraZeneca, the British-Swedish drugmaker and one of the world’s largest pharmaceutical companies by revenue, reportedly made a $10 billion offer to acquire Rhythm Pharmaceuticals, a biotech that treats rare, genetic forms of obesity. No rival bid has surfaced, but analysts at William Blair, Jefferies, and Leerink Partners expect one. Rhythm’s newly approved treatment for acquired hypothalamic obesity, Imcivree, positions the company as an attractive target for large-cap pharmaceutical companies like AstraZeneca.

This bid demonstrates just one of many efforts made by big pharma in the M&A space – looming patent cliffs are pushing big pharma to buy despite rising interest rates, while new U.S. tariffs are reshaping what it buys and where it builds.

Why Big Pharma Has to Buy

In the healthcare world, a patent gives a drugmaker a set number of years of exclusive sales. When it expires, cheaper generic or biosimilar competitors enter, and the original drug’s revenue can collapse within a few years.

Big pharma is currently approaching one of its largest patent cliffs in history, which could strip about $300 billion in revenue by 2030, roughly a sixth of the industry’s total. For example, Merck’s cancer drug Keytruda, which brought in more than $29 billion in 2024, is expected to lose patent protection by 2029.

Companies can’t replace that revenue fast enough through their own research, since a new drug can take a decade to develop, so buying a company that already has an approved or late-stage product is faster. AstraZeneca’s case demonstrates that logic: the company is aiming for $80 billion in sales by 2030, up from $58.7 billion last year. Rhythm would bring an approved drug that is growing quickly. Imcvirve sales reached $92.1 million in the third quarter of 2026, up 29% from the quarter before.

Buying Despite Higher Rates

Falling interest rates helped fuel pharma’s dealmaking revival. The Fed cut its benchmark rate to 3.50-3.75% by December 2025, and the XBI biotech index rose 35% that year. Lower rates make big acquisitions cheaper to finance, and higher biotech valuations make sellers more willing to negotiate.

That tailwind has reversed. In September 2026, the Fed raised its target range by a quarter point to 3.75-4.00%. At its October 28 meeting, it held rates there, saying inflation “remains elevated,” and two officials voted for another hike. Yet, dealmaking hasn’t slowed. The largest drugmakers have so much cash that financing costs matter less: Leerink Partners estimates they hold $188 billion in M&A firepower, and all but one have signaled they plan to use it.

Higher rates matter more on the other side of the table. Biotechs that don’t yet turn a profit burn through cash, and when outside funding gets expensive, selling looks more attractive. Rhythm is the exception: right before the AstraZeneca news broke, it secured access to up to $750 million through a loan facility led by KKR’s HealthCare Royalty and Blackstone Life Sciences. Because Rhythm doesn’t need to sell, it can hold out for a higher price, which is one reason analysts expect a bidding war.

How Tariffs Are Changing Deals

The newest force in pharma dealmaking is trade policy. In April 2026, the administration imposed Section 232 tariffs of 100% on imported patented drugs, which took effect July 31 for large drugmakers and September 29 for everyone else. Generics got a slower schedule: 0% for two years starting August 2026, then 100% in August 2028 and 200% in August 2029. Companies that strike deals with the government can avoid the steepest rates. By May, 17 large drugmakers had signed voluntary “most-favored-nation” pricing agreements, which require them to sell existing drugs to state Medicaid programs at the low prices paid in other wealthy countries. AstraZeneca was among the first to strike such a deal.

These rules change what an acquisition is worth. A drug made in the U.S., or owned by a company that already has a deal with Washington, carries less tariff risk than one made abroad. U.S. manufacturing capacity has become a target in its own right. On November 12, PAI Pharma bought Nexus Pharmaceuticals, a U.S. maker of hospital injectable drugs, expanding domestic production in a market prone to shortages. For large buyers like AstraZeneca, a pricing agreement with the government also removes a major source of uncertainty, which makes it easier to commit $10 billion to a deal like Rhythm.

What Could Slow Things Down

The biggest risk is inflation. If prices keep rising, partly because of tariffs, the Fed could raise rates again, making deals more expensive to finance and pushing down biotech valuations. With the 10-year Treasury yield closing near 5% on the day of the Fed’s October decision, that risk is real.

Trade policy is also unpredictable. In February 2026, the Supreme Court struck down an earlier set of reciprocal tariffs, and the pharma-specific rules have shifted several times since. That uncertainty makes it harder for buyers and sellers to agree on what a company is worth.

Finally, too many buyers are chasing too few good assets. Competition for approved and late-stage drugs can push prices higher than they should be. If a bidding war breaks out over Rhythm, the winner may end up overpaying.

What to Watch Next

Three signals will show where pharma M&A goes next. First, whether a rival bid for Rhythm appears and whether AstraZeneca raises its offer. Second, the Fed’s next rate decision, since another hike would test how much rising rates can slow deals. Third, whether acquirers start pairing their deals with commitments to manufacture in the U.S.

The broader lesson of the Rhythm bid is that cheap money is no longer what drives pharma dealmaking. Patent cliffs decide how much big pharma has to buy, and tariffs increasingly decide what it buys and where. Interest rates now mostly decide how expensive it gets.